Organon & Co. (NYSE:OGN) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its position in Organon & Co. (NYSE:OGN) by 4.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,432 shares of the company’s stock after selling 4,654 shares during the period. Public Employees Retirement System of Ohio’s holdings in Organon & Co. were worth $1,787,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Mercer Global Advisors Inc. ADV lifted its position in shares of Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after acquiring an additional 546 shares in the last quarter. Ballentine Partners LLC lifted its holdings in Organon & Co. by 3.0% in the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after purchasing an additional 552 shares in the last quarter. Sippican Capital Advisors boosted its stake in Organon & Co. by 4.3% during the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after purchasing an additional 627 shares during the last quarter. Commerce Bank grew its holdings in shares of Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after buying an additional 637 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in shares of Organon & Co. by 6.6% during the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Down 1.8 %

Shares of OGN stock opened at $14.51 on Thursday. Organon & Co. has a twelve month low of $13.14 and a twelve month high of $23.10. The stock has a market cap of $3.74 billion, a price-to-earnings ratio of 2.88, a PEG ratio of 0.81 and a beta of 0.75. The company’s 50-day moving average price is $16.25 and its 200-day moving average price is $19.05. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company earned $0.78 EPS. As a group, equities analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were given a $0.28 dividend. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.72%. Organon & Co.’s dividend payout ratio is currently 22.22%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the stock from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.